<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22356850</article-id>
      <article-id pub-id-type="pmc">3307482</article-id>
      <article-id pub-id-type="publisher-id">1746-1596-7-19</article-id>
      <article-id pub-id-type="doi">10.1186/1746-1596-7-19</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged <italic>PDGFRB </italic>genes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Chang</surname>
            <given-names>Hung</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>doctor.horngchang@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Chuang</surname>
            <given-names>Wen-Yu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>chuang.taiwan@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Sun</surname>
            <given-names>Chien-Feng</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>suncgj@cgmh.org.tw</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Barnard</surname>
            <given-names>Marc R</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>Marc.Barnard@umassmed.edu</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>School of Medicine, Chang Gung University, Taoyuan, Taiwan</aff>
      <aff id="I2"><label>2</label>Division of Hematology-Oncology Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kweishan, Taoyuan 333, Taiwan</aff>
      <aff id="I3"><label>3</label>Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan</aff>
      <aff id="I4"><label>4</label>Core Flow Cytometry Laboratory, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA</aff>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>2</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <fpage>19</fpage>
      <lpage>19</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>2</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2012 Chang et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Chang et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.diagnosticpathology.org/content/7/1/19"/>
      <abstract>
        <p>Concurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia (AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12)(q33;p13), which indicated presence of <italic>PDGFRB </italic>gene translocations. Therefore, this disease belongs to the new WHO category of myeloid and lymphoid neoplasms with abnormalities in <italic>PDGFRA, PDGFRB </italic>and <italic>FGFR1 </italic>genes. Although such genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML and T lymphoblastic lymphoma involving <italic>PDGFRB </italic>mutations. The patient was treated with cytarabine and daunomycin in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection. Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.</p>
      </abstract>
      <kwd-group>
        <kwd>Acute myeloid leukemia</kwd>
        <kwd>T lymphoblastic lymphoma</kwd>
        <kwd><italic>PDGFR </italic>genes</kwd>
        <kwd>Chromosomal translocation</kwd>
        <kwd>Transplantation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>In 2008, a new class of hematopoietic system disorders, myeloid and lymphoid neoplasms with eosinophilia and abnormalities in <italic>PDGFRA, PDGFRB </italic>and <italic>FGFR1 </italic>genes, was created by WHO [<xref ref-type="bibr" rid="B1">1</xref>]. Although most cases presented with myeloproliferative neoplasm (MPN) and eosinophilia, this group of diseases was known to develop into multiple lineages of hematologic malignancies both in animal models and human cases [<xref ref-type="bibr" rid="B2">2</xref>]. In humans, concurrent myeloid neoplasms and T lymphoblastic lymphoma have been reported with <italic>FIP1L1-PDGFRA </italic>fusion genes [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>] but not with any <italic>PDGFRB </italic>rearranged genes. Neoplastic ells bearing such mutations are susceptible to tyrosine kinase inhibitors and successful treatment experiences have been reported [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 41-year-old businessman presented with multiple subcutaneous nodules in the arms and trunk 3 weeks before admission. These nodules were rapidly enlarging but neither painful nor pruritic. He also reported several systemic symptoms including malaise, drenching night sweat and generalized arthralgia. His urine amount decreased markedly and he gained 3 kilograms before admission. At admission, subcutaneous nodules were found in his arms, trunk and thighs. Enlarged lymph nodes that were fixed, discrete and elastic were palpated in neck, axillary, and inguinal areas. Liver and spleen were not palpable. Marked general edema was observed. Other physical findings were unremarkable. A complete blood count revealed a hemoglobin level 10.9 g/L, a platelet count 53 &#xD7; 10<sup>9</sup>/L, a white cell count 70.7 &#xD7; 10<sup>9</sup>/L with 20% blasts, 3% promyelocytes, 7.5% myelocytes, 3% metamyelocytes, 31% neutrophils, 0.5% eosinopils, 24.3% monocytes and 10.8% lymphocytes. The liver biochemistry profiles were normal but the renal function tests showed creatinine 2.21 mg/dL, uric acid 15.5 mg/dL, lactate dehydrogenase 612 U/L, calcium 9.1 mg/dL, and phosphate 2.4 mg/dL. Under the impression of spontaneous tumor lysis syndrome, he was treated with hydration and rasburicase 0.15 mg/kilogram. His renal function and edema improved gradually. Meanwhile, a biopsy of the right inguinal lymph node was done. The sections showed fragments of lymphoid tissue with diffuse infiltrates of medium-sized lymphoid cells, which had fine chromatin and small nucleoli (Figure <xref ref-type="fig" rid="F1">1A</xref>). The tumor cells were positive for CD3 (Figure <xref ref-type="fig" rid="F1">1B</xref>), CD5 and TIA-1. A part of them were also positive for TdT (Figure <xref ref-type="fig" rid="F1">1C</xref>). They were negative for CD20, cyclin D1, myeloperoxidase (Figure <xref ref-type="fig" rid="F1">1D</xref>), CD4, CD8, CD30, CD56 and CD25. About 95% of the tumor cells were positive Ki-67. It was classified as T lymphoblastic lymphoma.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Histology of the lymph node biopsy. A</bold>. diffuse infiltrates of medium-sized lymphoid cells, which had fine chromatin and small nucleoli. <bold>B</bold>. tumor cells positive for CD3(Polyclonal). <bold>C</bold>.a part of tumor cells positive for TdT. <bold>D</bold>. tumor cells were negative for myeloperoxidase(Polyclonal).</p>
        </caption>
        <graphic xlink:href="1746-1596-7-19-1"/>
      </fig>
      <p>The bone marrow aspiration smear and biopsy revealed hypercellular bone marrow with myeloblasts accounting for 36.7% of nucleated cells (Figure <xref ref-type="fig" rid="F2">2A</xref>). All leukemic cells were positive for peroxidase (Figure <xref ref-type="fig" rid="F2">2B</xref>). A flow cytometric analysis revealed the leukemic cells were positive for CD13, CD33, CD14, CD15, CD65 and negative for CD34, CD117, CD56, CD7 and CD19. In addition, the immunohistochemical stain of the bone marrow tissue section showed the blast cells were strongly positive for myeloperoxidase but negative for TdT, CD10, CD2, CD5 and CD20. The diagnosis of AML was established. The chromosome analysis revealed the karyotype 46, XY, t(5;12)(q33;p13). There was no detectable <italic>AML1-ETO, CBFb-MYH11</italic>, or <italic>MLL-PTD </italic>fusion transcripts shown by reverse transcriptase polymerase chain reactions. A fluorescent in situ hybridization (FISH) analysis with dual color <italic>PDGFRB </italic>probes was performed on patient's BM sample. It was positive for <italic>PDGFRB </italic>translocations.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Bone marrow aspiration smear. A</bold>. myeloblasts accounting for 36.7% of nucleated cells. <bold>B</bold>. all leukemic cells positive for peroxidase.</p>
        </caption>
        <graphic xlink:href="1746-1596-7-19-2"/>
      </fig>
      <p>He received induction chemotherapy with cytarabine (100 mg/m<sup>2</sup>/day continuous infusion for 7 days) and daunomycin (50/m<sup>2</sup>/day for 3 days). Dexamethasone 20 mg/day in divided doses was given in the same time, tapered off in a month. He had complete regression of lymph nodes and skin lesions and complete remission of AML. He subsequently received 2 cycles of postremission chemotherapy (cycle 1: cytarabine 3 g/m<sup>2 </sup>for 6 doses; cycle 2: cytarabine 1 g/m<sup>2 </sup>for 6 doses and etoposide 100 mg/m<sup>2</sup>/day for 3 days). In the state of continued remission, he underwent allogeneic stem cell transplantation from an HLA-matched sibling donor. Eleven months after transplantation, he died of chronic graft versus host disease (GVHD) and related pulmonary infection.</p>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Concurrent myeloid and lymphoid malignancies are quite uncommon. The difficulty of diagnosis can be illustrated in the present case. At presentation, generalized subcutaneous tumors and lymphadenopathies led to the diagnosis of a high grade lymphoma. The pathological diagnosis of T lymphoblastic lymphoma was made unequivocally by typical morphology and detailed immunophenotypical studies. The clinical course was complicated with spontaneous tumor lysis syndrome, which typically occurred in high grade lymphoma and therefore supported the diagnosis of T lymphoblastic lymphoma. Although lymphoblastic lymphoma may involve bone marrow or peripheral blood, the results of bone marrow studies revealed the leukemic cells did not belong to the T-lineage. The strongly positive myeloperoxidase staining suggested the diagnosis of AML. This was further confirmed definitively by its typical immunophenotypical profile. Some leukemic cells of AML may occasionally express T cell markers. In our case, however, the leukemia cells was found negative for CD2, CD5 and CD7, making aberrant expression of AML relatively unlikely. The diagnosis of concomitant AML and T lymphoblastic lymphoma, was confirmed.</p>
      <p>Although it appears unusual, such concurrence is not coincidental. In English literature, similar cases have been reported. In 2007, Metzgerot et al. reported 7 cases of AML or T lymphoblastic lymphoma bearing <italic>FIP1L1-PDGFA </italic>fusion genes. In 2 cases, T lymphoblastic lymphoma was found synchronously with myeloid neoplasms (acute eosinophilic leukemia in one and MPN in the other) [<xref ref-type="bibr" rid="B4">4</xref>]. In 2008, Capovilla et al. reported another case of synchronous chronic eosinophilic leukemia and T lymphoblastic lymphoma. Like the previous report, the leukemic cells were found to bear <italic>FIP1L1-PDGFRA </italic>fusion genes [<xref ref-type="bibr" rid="B3">3</xref>]. It appears from these reports that such genetic aberrations may lead to mixed lineage differentiation. In contrast to the previous reports with <italic>PDGFRA </italic>gene rearrangements, the present case was found to bear t(5;12)(q33;p13). This translocation most likely involves <italic>PDGFRB </italic>genes mapped on chromosome 5p. This assumption was further confirmed by studies of FISH. Based on chromosomal mapping and prior literature reports, the most likely partner gene is <italic>ETV6 </italic>[<xref ref-type="bibr" rid="B10">10</xref>].</p>
      <p>In 2008 WHO classification, a new class of hematopoietic diseases, myeloid and lymphoid neoplasms with eosinophilia and abnormalities in <italic>PDGFRA, PDGFRB </italic>and <italic>FGFR1 </italic>genes, were introduced [<xref ref-type="bibr" rid="B1">1</xref>]. In such a classification system, all cases of concurrent myeloid neoplasms and T lymphomblastic lymphoma, including the present case, belong to the same category. While most cases of this entity presented with MPNs, the genetic aberrations have a wide spectrum of differentiations, including eosinophilia, myelodysplastic syndrome, chronic myelomonocytic leukemia, AML, B or T cell acute lymphoblastic leukemia, T lymphoblastic lymphoma, and disorders with mast cell proliferation [<xref ref-type="bibr" rid="B2">2</xref>]. Most cases with <italic>PDGFRA </italic>gene rearrangements manifest as MPNs, usually chronic eosinophilic leukemia. <italic>PDGFRB </italic>gene rearrangement cases typically present as MPNs which are almost always accompanied with eosinophilia. Aberrations of <italic>FGFR1 </italic>genes are also commonly associated with MPNs with eosinophilia. In particular, this genetic mutation is often associated with differentiation into both myeloid and lymphoid lineages. The most common lymphoid neoplasm is T lymphoblastic lymphoma. The concurrence of myeloid and lymphoid malignancies was reported both in human cases and animal models [<xref ref-type="bibr" rid="B2">2</xref>].</p>
      <p>While these reports revealed it is not uncommon for <italic>PDGFRA </italic>and <italic>FGFR1 </italic>genetically rearranged cells to differentiate into lymphoid neoplasms, hematologic diseases bearing <italic>PDGFRB </italic>mutations are rare [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The two largest series reported in literature included 22 and 9 cases respectively. <italic>PDGFRB </italic>rearranged cells are known to develop into B and T lineage lymphoma [<xref ref-type="bibr" rid="B2">2</xref>]. This differentiation pattern was well described in transgenic mice models [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. However, according to an extensive review by Holroyd et al, patients with <italic>PDGFRB </italic>mutations have not been known to develop lymphoid malignancies. This is somewhat surprising and may be explained by the rarity of such mutations among humans [<xref ref-type="bibr" rid="B2">2</xref>]. As a result, the case in the present article is the first case report of lymphoma and concurrent AML bearing <italic>PDGFRB </italic>gene mutations.</p>
      <p>Treatment of concurrent AML and T lymphoblastic lymphoma and AML is a clinical challenge. There is mounting evidence that <italic>PDGFRA, PDGFRB </italic>and <italic>FGFR1 </italic>entities respond well to tyrosine kinase inhibitors [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. However, tyrosine kinase inhibitors are expensive and still off-label for lymphoma. Therefore, we did not consider tyrosine kinase inhibitors as the frontline treatment in this case. In view of the simultaneous expression of myeloid and lymphoid lineage features, consideration of chemotherapeutic regimens is similar to that of bi-phenotypic leukemia. Bi-phenotypic leukemia is an uncommon disorder. No consensus protocol is available for treatment. Some studies suggest that bi-phenotypic leukemia has good responses to treatment directed against AML [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. As a result, we chose treatment that was based on cytarabine and daunomycin. Steroids were included in the induction phase and complete remission was achieved for both AML and lymphoma. The patient subsequently underwent sibling-matched, allogeneic stem cell transplantation, which was quite successful until the development of chronic GVHD. Although the patient died of GVHD and related infections, he remained free from both malignancies for at least 11 months after transplantation. We believe allogeneic stem cell transplantation is an effective, albeit risky treatment option. Clinicians should weigh the risk against potential benefits before deciding treatment strategies, especially when tyrosine kinase inhibitors have become relatively safe and effective options.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Some of the laboratory and genetic testing included in this study was done by surplus clinical samples. An informed consent to utilize the samples was available for review. The consent form was approved by the institution review board in Chang Gung Memorial Hospital.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>HC wrote this manuscript. WYC and CFS conducted the pathology interpretation and drafted the related parts in the article. MRB revised the article. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>This work was supported by grant DOH99-TD-C-111-006 from the Department of Health, Executive Yuan, Taiwan.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vardiman</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Thiele</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Arber</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Brunning</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Borowitz</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Porwit</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Le Beau</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Hellstrom-Lindberg</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bloomfield</surname>
            <given-names>CD</given-names>
          </name>
          <article-title>The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>937</fpage>
          <lpage>951</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-03-209262</pub-id>
          <pub-id pub-id-type="pmid">19357394</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Holroyd</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Macdonald</surname>
            <given-names>DH</given-names>
          </name>
          <article-title>The two faces of myeloproliferative neoplasms: molecular events underlying lymphoid transformation</article-title>
          <source>Leuk Res</source>
          <year>2011</year>
          <volume>35</volume>
          <fpage>1279</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="doi">10.1016/j.leukres.2011.05.037</pub-id>
          <pub-id pub-id-type="pmid">21722956</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Capovilla</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cayuela</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Bilhou-Nabera</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gardin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Letestu</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Baran-Marzak</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Fenaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Synchronous <italic>FIP1L1-PDGFRA</italic>-positive chronic eosinophilic leukemia and t-cell lymphoblastic lymphoma: a bilineal clonal malignancy</article-title>
          <source>Eur J Haematol</source>
          <year>2008</year>
          <volume>80</volume>
          <fpage>81</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">18028420</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Metzgeroth</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Walz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Score</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Siebert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schnittger</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Popp</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Erben</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mix</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Muller</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Beneke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Muller</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Del Valle</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Aulitzky</surname>
            <given-names>WE</given-names>
          </name>
          <name>
            <surname>Wittkowsky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Schmitz</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Schulte</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Muller-Hermelink</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hodges</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Whittaker</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Diecker</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Dohner</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Schuld</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hehlmann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Reiter</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Recurrent finding of the <italic>FIP1L1-PDGFRA </italic>fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic t-cell lymphoma</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1183</fpage>
          <lpage>1188</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2404662</pub-id>
          <pub-id pub-id-type="pmid">17377585</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Apperley</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Gardembas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Melo</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Russell-Jones</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bain</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Baxter</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Chase</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chessells</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Colombat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dearden</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Dimitrijevic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mahon</surname>
            <given-names>FX</given-names>
          </name>
          <name>
            <surname>Marin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nikolova</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Olavarria</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Silberman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schultheis</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <fpage>481</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa020150</pub-id>
          <pub-id pub-id-type="pmid">12181402</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Elling</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Erben</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Walz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Frickenhaus</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schemionek</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Stehling</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Serve</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hofmann</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Berdel</surname>
            <given-names>WE</given-names>
          </name>
          <name>
            <surname>Muller-Tidow</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Reiter</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Koschmieder</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Novel imatinib-sensitive <italic>PDGFRA</italic>-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>117</volume>
          <fpage>2935</fpage>
          <lpage>2943</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2010-05-286757</pub-id>
          <pub-id pub-id-type="pmid">21224473</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Helbig</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Moskwa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hus</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Piszcz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Swiderska</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Urbanowicz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Calbecka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Seferynska</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Razny</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rodzaj</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kyrcz-Krzemien</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Durable remission after treatment with very low doses of imatinib for <italic>FIP1L1-PDGFRA </italic>-positive chronic eosinophilic leukaemia</article-title>
          <source>Cancer Chemother Pharmacol</source>
          <year>2011</year>
          <volume>67</volume>
          <fpage>967</fpage>
          <lpage>969</lpage>
          <pub-id pub-id-type="doi">10.1007/s00280-011-1582-3</pub-id>
          <pub-id pub-id-type="pmid">21327932</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rathe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kristensen</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Moller</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Carlsen</surname>
            <given-names>NL</given-names>
          </name>
          <article-title>Myeloid neoplasm with prominent eosinophilia and pdgfra rearrangement treated with imatinib mesylate</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2010</year>
          <volume>55</volume>
          <fpage>730</fpage>
          <lpage>732</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.22655</pub-id>
          <pub-id pub-id-type="pmid">20589620</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Walz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Erben</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ritter</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bloor</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Metzgeroth</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Telford</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Gesk</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Score</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hofmann</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Reiter</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Response of <italic>ETV6-FLT3</italic>-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of <italic>FMS</italic>-like tyrosine kinase 3</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>2239</fpage>
          <lpage>2242</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-03-343426</pub-id>
          <pub-id pub-id-type="pmid">21705501</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Golub</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Barker</surname>
            <given-names>GF</given-names>
          </name>
          <name>
            <surname>Lovett</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>DG</given-names>
          </name>
          <article-title>Fusion of PDGF receptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation</article-title>
          <source>Cell</source>
          <year>1994</year>
          <volume>77</volume>
          <fpage>307</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1016/0092-8674(94)90322-0</pub-id>
          <pub-id pub-id-type="pmid">8168137</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tomasson</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>IR</given-names>
          </name>
          <name>
            <surname>Hasserjian</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Udomsakdi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>McGrath</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Schwaller</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Druker</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>DG</given-names>
          </name>
          <article-title>TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor</article-title>
          <source>Blood</source>
          <year>1999</year>
          <volume>93</volume>
          <fpage>1707</fpage>
          <lpage>1714</lpage>
          <pub-id pub-id-type="pmid">10029600</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ritchie</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Aprikyan</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Bowen-Pope</surname>
            <given-names>DF</given-names>
          </name>
          <name>
            <surname>Norby-Slycord</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Conyers</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bartelmez</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sitnicka</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Hickstein</surname>
            <given-names>DD</given-names>
          </name>
          <article-title>The TEL-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice</article-title>
          <source>Leukemia</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>1790</fpage>
          <lpage>1803</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2401494</pub-id>
          <pub-id pub-id-type="pmid">10557054</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Yeom</surname>
            <given-names>JO</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>SG</given-names>
          </name>
          <article-title>Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13)</article-title>
          <source>Acta Haematol</source>
          <year>2008</year>
          <volume>119</volume>
          <fpage>57</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1159/000115966</pub-id>
          <pub-id pub-id-type="pmid">18268406</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Serefhanoglu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Buyukasik</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Goker</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sayinalp</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ozcebe</surname>
            <given-names>OI</given-names>
          </name>
          <article-title>Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series</article-title>
          <source>J Natl Med Assoc</source>
          <year>2009</year>
          <volume>101</volume>
          <fpage>270</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="pmid">19331261</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Mi</surname>
            <given-names>YC</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>XM</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>JX</given-names>
          </name>
          <article-title>study on the clinical characteristics of adult biphenotypic acute leukaemia</article-title>
          <source>Zhonghua XueYeXueZa Zhi</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>18</fpage>
          <lpage>21</lpage>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zheng</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>W</given-names>
          </name>
          <article-title>What is the optimal treatment for biphenotypic acute leukemia?</article-title>
          <source>Haematologica</source>
          <year>2009</year>
          <volume>94</volume>
          <fpage>1778</fpage>
          <lpage>1780</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2009.014829</pub-id>
          <pub-id pub-id-type="pmid">19996120</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
